Company news
Mannkind Corporation (NASDAQ:MNKD) news
Every Mannkind Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Ac...
August 13, 2026
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of It...
July 29, 2026
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
July 28, 2026
MannKind Announces $50 Million Private Placement
July 24, 2026
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the...
July 24, 2026
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
June 23, 2026
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric C...
June 5, 2026
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient i...
June 3, 2026
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
May 29, 2026
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and O...
May 29, 2026
MannKind to Present at Jefferies Global Healthcare Conference
May 27, 2026
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with...
May 27, 2026
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
May 6, 2026
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
March 9, 2026
MannKind Announces Settlement of Convertible Senior Notes
March 5, 2026
MannKind to Participate in Upcoming Investor Conferences
March 4, 2026
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 18, 2026
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabete...
February 9, 2026
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections ...
January 26, 2026
MannKind Provides Business Updates and 2026 Growth Drivers
January 8, 2026
MannKind Shares FUROSCIX® Business Updates
December 23, 2025
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the T...
December 1, 2025
MannKind to Present at the Jefferies Global Healthcare Conference
November 11, 2025
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
November 10, 2025
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
November 6, 2025
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
October 29, 2025
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Chi...
October 13, 2025
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
October 7, 2025
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
September 29, 2025
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
August 27, 2025
MannKind to Present at Upcoming Investor Conferences
August 27, 2025
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung D...
August 25, 2025
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
August 6, 2025
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
August 6, 2025
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
July 30, 2025
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th ...
June 9, 2025
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
May 27, 2025
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
May 1, 2025
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
April 7, 2025
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference...
March 10, 2025
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 26, 2025
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
February 19, 2025
MannKind Expands Executive Leadership Team
January 6, 2025
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
December 18, 2024
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
December 16, 2024